SCN1A gene therapy for Dravet syndrome p.Asp79Glu: precision upregulation vs. gene replacement strategies

Dravet syndrome caused by SCN1A haploinsufficiency variants like p.Asp79Glu presents a gene therapy challenge distinct from pure loss-of-function diseases: Nav1.1 is expressed in inhibitory interneurons, and restoring balanced channel function — not simply maximizing expression — is critical. Asp79 resides in the N-terminal intracellular domain of Nav1.1 and is conserved across voltage-gated sodium channel paralogs; the D79E substitution likely alters channel gating kinetics. Two main gene therapy paradigms are under clinical or late preclinical development: (1) CRISPR-based activation (CRISPRa) of the endogenous wild-type SCN1A allele, and (2) AAV-delivered engineered SCN1A transgenes using regulatory element approaches to circumvent the 6 kb coding sequence exceeding AAV packaging limits.

Encoded Therapeutics (now Stoke Therapeutics/Ipsen pipeline) developed ETX101, an AAV9-based gene therapy delivering a transcription factor (engineered SCN1A-selective activator) to upregulate endogenous SCN1A specifically in GABAergic interneurons using the Dlx5/6 enhancer. ETX101 received FDA Rare Pediatric Disease designation. Stoke Therapeutics developed STK-001 (zorevunersen), an ASO that modulates SCN1A pre-mRNA splicing to increase productive mRNA and Nav1.1 protein. The Phase 2 MONARCH study showed dose-dependent reduction in convulsive seizure frequency in Dravet patients. For missense variants like p.Asp79Glu that produce a dysfunctional (rather than absent) protein, the therapeutic calculus is more complex: upregulating the wild-type allele via CRISPRa or ASO is rational, but the mutant allele continues to produce a potentially dominant-negative channel subunit. Preclinical work in Scn1a+/- mice has shown that restoring ~50% of normal Nav1.1 levels is sufficient to rescue seizures and premature death.

SCN1A full-length cDNA (6,030 bp) exceeds the ~4.7 kb AAV packaging limit, preventing conventional single-vector gene replacement. Dual-vector or mini-gene strategies reduce transduction efficiency. Cell-type-specific expression is essential — SCN1A overexpression in excitatory neurons could paradoxically worsen seizures. For the p.Asp79Glu missense variant specifically, the mutant channel may retain partial function or exert dominant-negative effects, meaning that simply adding more wild-type protein may not fully correct the phenotype if mutant-wild type heteromeric channels form. Long-term expression stability and the risk of insertional mutagenesis (for integrating vectors) or immune responses to AAV capsids remain unresolved. Developmental timing is critical: most Dravet patients present with seizures in the first year of life, and early intervention before extensive seizure-related brain injury is likely important for optimal outcomes.